BlackRock’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

BlackRock’s Portfolio PARN Stock Details PARN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-91,911	Closed	-$63K	–	5163
2016 Q4	$63K	Sell	91,911 -9,216	-9%	-$11K	﹤0.01%	2825
2016 Q3	$144K	Buy	101,127 +16,200	+19%	+$25.1K	﹤0.01%	2373
2016 Q2	$138K	Sell	84,927 -27,946	-25%	-$51.4K	﹤0.01%	2332
2016 Q1	$240K	Sell	112,873 -2,315	-2%	-$6.39K	﹤0.01%	1696
2015 Q4	$447K	Buy	115,188 +3,600	+3%	+$13.7K	﹤0.01%	1545
2015 Q3	$384K	Buy	+111,588	New	+$474K	﹤0.01%	1556

Other funds holding PARN

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock's PARN Position: Q1 2017 in Review

BlackRock sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q1 2017, closing a stake of 91,911 shares — an estimated $63K sold.

BlackRock first reported a position in PARN in Q3 2015 and held it in 6 quarters. The position peaked at $447K in Q4 2015. 2 funds tracked by Wall St. Rank hold PARN as of Q1 2017.

BlackRock reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q1 2017 after selling out during the quarter.
BlackRock sold 91,911 Parnell Pharmaceuticals Holdings Ltd shares in Q1 2017, an estimated $63K.
BlackRock first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q3 2015 and held it in 6 quarters.
BlackRock's Parnell Pharmaceuticals Holdings Ltd position peaked at $447K in Q4 2015.
2 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q1 2017.

Based on BlackRock's 13F filing for Q1 2017, filed 12 May 2017.